Abstract
Biomedical research cannot succeed without funding, knowledgeable staff, and appropriate infrastructure. There are however equally important but intangible factors that are rarely considered in planning large multidisciplinary endeavors or evaluating their success. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial required extensive collaborations between individuals from many fields, including clinicians, clinical trialists, and administrators; it also addressed questions across the spectrum of cancer prevention and control. In this manuscript, we examine the experiences and opinions of trial staff regarding the building of successful relationships in PLCO. We summarize, in narrative form, data collected using open-ended questionnaires that were administered to the National Cancer Institute project officers, coordinating center staff, screening center principal investigators, and screening center coordinators in 2015, about 3 years after publication of the final primary trial manuscript. Trust, respect, listening to others, and in-person interaction were frequently mentioned as crucial to building successful relationships.
Keywords: Cancer screening, collaboration, multidisciplinary, PLCO, randomized controlled trials as subject, team science.
Reviews on Recent Clinical Trials
Title:Building Successful Relationships in the PLCO Cancer Screening Trial
Volume: 10 Issue: 3
Author(s): Victoria Jenkins, Susan Yurgalevitch, Lance A. Yokochi, Vicki Shambaugh, Douglas Reding, Philip C. Prorok, Sheryl L. Ogden, Barbara O’Brien, Karen Lappe, Christine C. Johnson, Pamela M. Marcus, Rachel Jaggi, Darlene Higgins, Lisa H. Gren, John K. Gohagan, Timothy R. Church, Jeffery Childs, Saundra S. Buys and Karen G. Broski
Affiliation:
Keywords: Cancer screening, collaboration, multidisciplinary, PLCO, randomized controlled trials as subject, team science.
Abstract: Biomedical research cannot succeed without funding, knowledgeable staff, and appropriate infrastructure. There are however equally important but intangible factors that are rarely considered in planning large multidisciplinary endeavors or evaluating their success. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial required extensive collaborations between individuals from many fields, including clinicians, clinical trialists, and administrators; it also addressed questions across the spectrum of cancer prevention and control. In this manuscript, we examine the experiences and opinions of trial staff regarding the building of successful relationships in PLCO. We summarize, in narrative form, data collected using open-ended questionnaires that were administered to the National Cancer Institute project officers, coordinating center staff, screening center principal investigators, and screening center coordinators in 2015, about 3 years after publication of the final primary trial manuscript. Trust, respect, listening to others, and in-person interaction were frequently mentioned as crucial to building successful relationships.
Export Options
About this article
Cite this article as:
Jenkins Victoria, Yurgalevitch Susan, A. Yokochi Lance, Shambaugh Vicki, Reding Douglas, C. Prorok Philip, L. Ogden Sheryl, O’Brien Barbara, Lappe Karen, C. Johnson Christine, M. Marcus Pamela, Jaggi Rachel, Higgins Darlene, H. Gren Lisa, K. Gohagan John, R. Church Timothy, Childs Jeffery, S. Buys Saundra and G. Broski Karen, Building Successful Relationships in the PLCO Cancer Screening Trial, Reviews on Recent Clinical Trials 2015; 10 (3) . https://dx.doi.org/10.2174/1574887110666150731131743
DOI https://dx.doi.org/10.2174/1574887110666150731131743 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pluronic-Based Core/Shell Nanoparticles for Drug Delivery and Diagnosis
Current Medicinal Chemistry Molecular Imaging of Apoptosis for Early Prediction of Therapy Efficiency
Current Pharmaceutical Design Is Brain-Derived Neurotrophic Factor: A Common Link Between Neurodegenerative Disorders and Cancer?
Current Alzheimer Research The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Determination of Binding Constant and Stoichiometry for Antibody-Antigen Interaction with Surface Plasmon Resonance
Current Proteomics MRI Evaluation of Treatment Response for Local Therapies for Malignant Liver Lesions
Current Cancer Therapy Reviews Development of an Intracellular, DNA Methyltransferase-Specific, and Gene-Specific Assay for Studying Dynamic DNA Methylation
Current Pharmaceutical Design Analytical Methods for Metallothionein Detection
Current Analytical Chemistry Exosomal MicroRNAs in Tumoral U87 MG Versus Normal Astrocyte Cells
MicroRNA A “Crazy Paving” Pattern on CT Scan in a Patient Treated with Pembrolizumab
Current Drug Safety Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Contrast Agents in X-Ray Computed Tomography and Its Applications in Oncology
Anti-Cancer Agents in Medicinal Chemistry Respiratory Motion Management in PET/CT: Applications and Clinical Usefulness
Current Radiopharmaceuticals QSAR and Docking Based Semi-synthesis and in vitro Evaluation of 18 β-glycyrrhetinic Acid Derivatives Against Human Lung Cancer Cell Line A-549
Medicinal Chemistry General Aspects of Metal Toxicity
Current Medicinal Chemistry Arachidonic Acid Induces the Migration of MDA-MB-231 Cells by Activating Raft-associated Leukotriene B4 Receptors
Clinical Cancer Drugs HIV-1 Vpr: Enhancing Sensitivity of Tumors to Apoptosis
Current Drug Delivery TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease
Current Topics in Medicinal Chemistry Cordycepin Suppresses Integrin/FAK Signaling and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry